CA-DRISHTI-TECHNOLOGIES
24.3.2022 11:02:14 CET | Business Wire | Press release
Drishti Technologies, Inc. (Drishti), whose AI-powered manufacturing technology uses video analytics, data and insights to bring significant benefits to manufacturers and their employees, and HELLA (FRA:HLE) a tier-one automotive supplier, today announced the latest in a joint effort to further increase operational efficiency with a second successful combined project in Dhankot, India. HELLA is an internationally positioned automotive supplier globally recognized for its lean practices and is committed to investing in the latest technologies to drive human productivity and improve manufacturing outcomes.
With Drishti cameras and streaming video analysis enabled on one of HELLA’s sensor product lines, the HELLA team made a series of previously concealed discoveries. First, the massive volume of cycle time data available from Drishti quickly revealed slowdowns in stations that were not originally the focus of improvement efforts. Second, by watching video footage from the identified station, the team understood that the physical station configuration was slowing down the line associates.
In fact, the station setup was causing ergonomic concerns. Because the line associate was reaching with his right arm across to the left side of the station, each cycle required a twisting motion that led to fatigue.
“Because our focus had been on the station we thought was the bottleneck, we had overlooked this potential for slowdowns and fatigue,” said Ram Singh Khangarote, operational excellence and operation product manager, HELLA Dhankot. “Within a few minutes of viewing the video footage from Drishti, our team had ideas to reconfigure the station to make it more comfortable for the line associates, and shortening every cycle time. And most importantly, our line associates are healthier, happier and more productive.”
Finally, with Drishti, because the team in Dhankot learned the true cause of line slowdowns, they were able to improve line balancing. The Drishti investment paid for itself in less than six months.
“This is the second instance of finding significant improvement opportunities using Drishti. In 2020, we reduced cycle times in our Guanajuato, Mexico plant . Now we’re seeing value in Dhankot, as well,” said Huri Mendoza, head of operational excellence, HELLA. “Drishti’s technology perfectly complements our goal of achieving operational excellence by augmenting our extremely capable workforce and empowering them with the tools they need to perform their jobs even better.”
The Dhankot plant deployment is one of several ongoing collaborations between HELLA and Drishti. Drishti streams video at every station on a line, then uses proprietary AI networks to translate video streams into data, a technique called action recognition. The line-level data on cycles and actions helps manufacturers improve productivity and quality while improving standardized work adherence.
“Drishti’s action recognition technology provides manufacturers with a clear competitive edge, as they can see improvement opportunities on assembly lines that are otherwise hidden,” said Gary Jackson, CEO, Drishti. “HELLA’s success with Drishti is in line with what we’re seeing across the automotive industry, as well as in other verticals like electronics and medical devices. The future of automated video analysis, which creates insights on people at work, runs through Drishti.”
About Drishti
Drishti’s AI-powered video analytics technology augments human workers and provides visibility and insights that transform the pace and impact of manual assembly line improvement. Manufacturers use Drishti to anchor true digital transformation, driving sweeping improvements in quality costs, efficiency gains & time-to-proficiency for line associate training. And line associates rely on Drishti to be more consistent and efficient, becoming even more valuable on the factory floor. Drishti has been recognized as a World Economic Forum Technology Pioneer and a Forbes AI 50 company, among others. For more information, visit drishti.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
